A guide to tadalafil safety in children under 12, covering FDA labeling, approved pediatric indications, dosing data from clinical trials, and monitoring requirements.
A comprehensive drug-drug interaction table and prescribing guide for GIP/GLP-1 dual agonists (tirzepatide class), written at MD/PharmD level with primary-source citations.
A clinical comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) covering efficacy, cost, insurance access, dosing, and who each drug suits best.
A detailed comparison of sermorelin acetate and CJC-1295 modified GRF covering mechanism, clinical evidence, dosing protocols, side effects, and how to choose between them.
A comparison of CJC-1295 and MK-677 (ibutamoren): how each raises GH, what the clinical trials show, the rationale for combining them, and the real risks you need to know before starting.
A clinical deep-dive comparing tesamorelin (Egrifta) and ibutamoren (MK-677) in HIV lipodystrophy, older adults, metabolic syndrome, and other special populations. Includes trial data, dosing, safety, and switching guidance.
Compare the long-term evidence for BPC-157 and GHK-Cu, including follow-up, clinical outcomes, topical versus injectable formulations, and durability claims.
A head-to-head clinical comparison of Epitalon (tetrapeptide) and AOD-9604 (HGH fragment 176-191) examining how well each peptide's effects hold up over months and years, with dosing guidance and switching criteria.
A clinical comparison of oral minoxidil and dutasteride (Avodart) covering titration protocols, side-effect profiles, onset timelines, and how to decide between them for androgenetic alopecia.
A comparison of oral minoxidil vs topical minoxidil for hair loss, including the evidence base for combining both, dosing protocols, and safety considerations.
A head-to-head clinical comparison of oral low-dose minoxidil and topical tretinoin titration protocols, side-effect profiles, and tolerability data to help patients and clinicians choose the right approach.
How secondary hypogonadism relapses after treatment, which reversible causes drive it, and how to choose between enclomiphene, hCG, and testosterone therapy based on fertility goals and monitoring findings.
A clinical deep-dive into the unresolved debates around menopause-related weight gain, including whether estrogen loss causes fat redistribution, the role of HRT, GLP-1 agents, and what current guidelines get wrong.
A look at the unresolved diagnostic, metabolic, and treatment controversies in polycystic ovary syndrome, framed around what a patient or clinician actually needs to decide.
Evidence-based dosing guide for dulaglutide (Trulicity) in adolescents aged 12, 17 with type 2 diabetes. Covers FDA-approved doses, titration schedules, safety monitoring, and clinical trial data.
A guide to dulaglutide (Trulicity) dosing for young adults aged 18, 29 with type 2 diabetes, covering starting doses, titration schedules, injection technique, fertility considerations, and cardiovascular evidence from the REWIND trial.
A clinician-level review of how dulaglutide (Trulicity) affects mental health and mood, covering GLP-1 receptor signaling in the brain, trial data, FDA safety communications, and practical monitoring guidance.
A clinical deep-dive into how dutasteride (Avodart) affects liver function, what the trial data shows, when to monitor LFTs, and which patients face the highest risk.
Board-reviewed clinical guide to dutasteride (Avodart) travel protocols, timezone-shift dosing, storage rules, and what to do when doses are missed mid-journey.
A structured approach to diagnosing why testosterone stalls on enclomiphene citrate: how to tell a lab-timing artifact from SHBG elevation, thyroid or prolactin interference, medication effects, or primary testicular failure, and when to reconsider the plan.
A clinical review of how eszopiclone (Lunesta) may affect libido, arousal, and hormonal signaling, what is established versus unproven, and a practical framework for sorting sedation from true sexual suppression.
How SRD5A1/SRD5A2 polymorphisms, CYP3A4 variants, and androgen-receptor genetics shape finasteride response, adverse-effect risk, and dosing decisions, with PubMed-cited evidence.
A clinician-level review of GHK-Cu (copper tripeptide) and its documented effects on metabolism, mitochondrial function, and energy expenditure, with primary-literature citations and dosing context.
A detailed guide to Anthem's tirzepatide (Mounjaro) coverage policies, prior authorization requirements, formulary tiers, appeal strategies, and cost-saving options, prepared by the HealthRX.com Editorial Team.
A explanation of why Calibrate uses liraglutide (Saxenda®) for metabolic health, including its mechanism, FDA approval history, dosing, side effects, and how it compares to newer GLP-1 agents.
A guide to the Jatenzo (oral testosterone undecanoate) and atorvastatin drug interaction, covering CYP3A4 mechanisms, lipid monitoring, dose adjustment, and patient counseling.
Can you take sildenafil with omeprazole or pantoprazole? A guide covering the CYP enzyme mechanism, clinical significance, dosing, and monitoring for this drug interaction.
A guide covering the pharmacokinetic and pharmacodynamic interaction between tretinoin topical and progesterone HRT, including CYP pathways, monitoring, dosing, and patient counseling backed by primary literature.
A complete clinical guide to tesamorelin's vaccine interaction profile, covering live versus inactivated vaccines, immune function, alcohol use, and practical dosing guidance for patients on Egrifta therapy.
A clinical review of the thymosin alpha-1 and alcohol interaction profile, covering immunologic mechanisms, hepatic effects, practical dosing guidance, and safety considerations for patients on thymalfasin therapy.
A clinical evidence review of the pharmacokinetic and pharmacodynamic considerations between semaglutide 2.4 mg (Wegovy) and finasteride, including what is established, what is plausible but unproven, and what should be verified before assuming the combination is risk-free.
Evidence-based isotretinoin dosing for adolescents aged 12, 17, covering starting doses, cumulative targets, iPLEDGE requirements, mental-health monitoring, and growth considerations backed by primary clinical sources.
Complete guide to isotretinoin dosing for adults aged 30 to 49, covering starting doses, cumulative targets, dose adjustments, iPLEDGE requirements, and what to expect during a course of treatment.
A guide to understanding your Free T4 lab result, including normal ranges, what high and low values mean, and when treatment is needed.
How to read your DNA methylation biological age test: what GrimAge, Horvath, and PhenoAge scores mean, what counts as a normal range, and how rate-of-change over serial testing guides clinical action.
Board-reviewed guide to how food intake, fasting duration, alcohol, and diet quality affect FibroScan (VCTE) results, with normal ranges, optimal values, and clinical protocols for MASLD staging.
Everything you need to know about testing your Omega-3 index at home with a finger-prick blood spot card, what the numbers mean, and how to reach the cardioprotective target range backed by clinical evidence.
A guide to polysomnography interpretation across sexes and menstrual cycle phases, including OSA screening thresholds, hormone interactions, and how to optimize sleep architecture for TRT, HRT, and GLP-1 patients.
See telomere length reference ranges by age decade and what your T/S ratio or kb value means. Not a diagnostic test, but a research-based wellness marker.
No fasting required, but food, exercise and dehydration can skew uACR results 20-100%. Learn the best collection window and prep tips for accurate readings.
How liraglutide is dosed and titrated in adults ages 50 to 64, including the FDA-approved titration schedule, cardiovascular and renal considerations, polypharmacy risks, and where trial evidence does and does not directly speak to this age group.
A guide to using tirzepatide (Mounjaro) for metabolic syndrome, covering trial evidence, dosing schedules, and real-world outcomes.
Mounjaro has no FDA approval and no controlled trials in children under 12. See what the evidence shows and current AAP guideline recommendations instead.
A guide to using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for NASH, covering the evidence base, GRADE ratings, required monitoring, and what FDA approval means for this indication.
A clinical week-by-week guide to oral minoxidil for hair loss. Learn what happens at weeks 1, 2, 3, and 4, what side effects to watch for, and what the evidence says about dose, response, and long-term results.
A guide to adjusting low-dose oral minoxidil dosing schedules during travel, jet lag, and timezone changes, with pharmacokinetic rationale and practical protocols.
A deep dive into Ozempic (semaglutide 0.5 to 2.0 mg) real-world evidence from registries, observational cohorts, and post-marketing data. Covers mechanism, effectiveness, safety signals, and how RWE compares to SUSTAIN trial results.
A breakdown of AOD-9604's federal and Ohio-specific legal status, FDA regulatory classification, compounding pharmacy rules, and how patients can access it through a licensed provider.
A guide to PT-141 (Bremelanotide) legal status in Arizona, covering FDA approval, 503A/503B compounding rules, state pharmacy board requirements, and how to get a valid prescription.
A guide to PT-141 (Bremelanotide) legal status in Kentucky, covering FDA approval, federal compounding law, state pharmacy board rules, and how to get a valid prescription.
A guide to PT-141 (Bremelanotide) legal status in Wisconsin, covering FDA approval, federal scheduling, 503A/503B compounding rules, and how to get a valid prescription.
A guide to TB-500's legal status in Minnesota, covering federal FDA rules, 503A/503B compounding pharmacy law, state pharmacy board requirements, and the only lawful paths to obtain thymosin beta-4 peptide.
A complete guide to the legal status of TB-500 (Thymosin Beta-4) in Ohio, covering FDA regulations, 503A/503B compounding pharmacy rules, state pharmacy board requirements, and how patients can obtain TB-500 with a valid prescription.
A guide to the federal and Georgia-specific legal framework for Egrifta (tesamorelin), including FDA approval status, 503A/503B compounding rules, prescription requirements, and how Georgia residents can access this peptide legally.
A guide to the federal and Texas-specific legal framework for Egrifta (tesamorelin): FDA approval status, prescription requirements, 503A/503B compounding rules, and how Texas residents can access it through a licensed provider.
A guide to the federal and Arizona-specific legal framework for Thymosin Alpha-1, including FDA status, 503A/503B compounding rules, and how to obtain a valid prescription.
A breakdown of Thymosin Alpha-1's federal and Arizona-specific legal status, how compounding pharmacy rules apply, and what patients need to obtain it lawfully.
A guide to the federal and Missouri state legal framework governing Thymosin Alpha-1, including FDA bulk-drug status, 503A/503B compounding rules, and how patients can access it legally.
A structured clinical protocol for using sermorelin in recalcitrant chronic tendinopathy (Achilles, patellar, rotator cuff), including dosing, frequency, monitoring labs, and the current evidence base.
Step-by-step MD-level guidance on reconstituting AOD-9604 peptide: bacteriostatic water volumes, insulin syringe selection, needle gauge, and dosing calculator tips. prepared by the HealthRX.com Editorial Team.